ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Dysfunction in Allergic Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00189228
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : January 23, 2013
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Mark Schuyler, University of New Mexico

Brief Summary:
We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Condition or disease Intervention/treatment Phase
Asthma Drug: Xolair Not Applicable

Detailed Description:
Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma
Study Start Date : September 2005
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Omalizumab

Arm Intervention/treatment
Experimental: xolair
This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
Drug: Xolair
Patients are administered Xolair




Primary Outcome Measures :
  1. anti-KLH antibody [ Time Frame: 6 months ]
    Asthma and control patients are immunized with KLH



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189228


Locations
United States, New Mexico
UNM HSC
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Study Director: Mark Schuyler, MD UNM HSC

Responsible Party: Mark Schuyler, Professor of Medicine, University of New Mexico
ClinicalTrials.gov Identifier: NCT00189228     History of Changes
Obsolete Identifiers: NCT00201097
Other Study ID Numbers: UNMSCOR
R01HL044253 ( U.S. NIH Grant/Contract )
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: January 23, 2013
Last Verified: January 2013

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Omalizumab
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents